MARKET

IPCIF

IPCIF

Intellipharmaceu
OTCMQB
0.090
0.000
0.00%
Closed 16:00 09/28 EDT
OPEN
--
PREV CLOSE
0.090
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.300
52 WEEK LOW
0.080
MARKET CAP
2.96M
P/E (TTM)
-0.5995
1D
5D
1M
3M
1Y
5Y
Intellipharmaceutics Signs an Exclusive License & Supply Agreement with Taro Pharmaceuticals Inc. for Desvenlafaxine Extended-Release Tablets
Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI)("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral s...
ACCESSWIRE · 08/16 12:00
Intellipharmaceutics International GAAP EPS of -$0.03
Intellipharmaceutics International press release (<a href="https://seekingalpha...
Seekingalpha · 07/21 21:15
Intellipharmaceutics Announces Second Quarter 2022 Results
Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI)("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral s...
ACCESSWIRE · 07/21 18:50
-- Earnings Flash (IPCIF) INTELLIPHARMACEUTICS INTERNATIONAL Reports Q1 Loss $-0.03
MT Newswires · 04/14 16:48
Intellipharmaceutics International reports Q1 results
Intellipharmaceutics International (IPCIF): Q1 GAAP EPS of -$0.04.Cash balance of $202.67K.Press Release
Seekingalpha · 04/14/2021 11:51
Intellipharmaceutics International reports FY results
Intellipharmaceutics International (IPCIF): FY GAAP EPS of -$0.14.Revenue of $1.4M (-59.8% Y/Y)Press Release
Seekingalpha · 03/01/2021 14:28
Intellipharmaceutics International reports Q3 results
Intellipharmaceutics International (IPCIF): Q3 GAAP EPS of $0.04.Revenue of $0.33M (-80.5% Y/Y)Press Release
Seekingalpha · 10/15/2020 21:24
FDA Ad Com thumbs down on Intellipharmaceutics' oxycodone ER
seekingalpha · 01/16/2020 03:02
More
About IPCIF
Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products, and product candidates in various stages of development, in therapeutic areas that include neurology and cardiovascular. Its pipeline of products includes Rexista Oxycodone, Regabatin XR, Generic Focalin XR, Generic Effexor XR, Generic Protonix, Generic Glucophage XR, Generic Seroquel XR, Generic Lamictal XR, Generic Keppra XR, Generic Pristiq and Generic Ranexa. Its generic product candidates also include Trazodone hydrochloride extended-release tablets and Carvedilol phosphate extended-release capsules.

Webull offers kinds of IntelliPharmaCeutics Intl Inc (USA) stock information, including OTCMQB:IPCIF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IPCIF stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IPCIF stock methods without spending real money on the virtual paper trading platform.